Frontage has announced completion of its Pennsylvania site expansion to boost its offering of bioanalytical services for late-stage cell and gene therapies developers.
Frontage Clinical Services has expanded its site in New Jersey to accommodate nicotine-related studies and is developing a portfolio of assays to evaluate tobacco-specific biomarkers.